{"entity":{"id":"nct07136779","kind":"trial","name":"First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies","aka":[],"tldr":"A phase 1/2 trial of VBC101 in advanced solid tumours, run by VelaVigo Bio Inc, now recruiting.","summary":"First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT07136779 by VelaVigo Bio Inc, with 310 participants planned, started 2025-09-23 and due to reach its primary completion in 2027-07-01. Interventions recorded: VBC101.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07136779","url":"https://clinicaltrials.gov/study/NCT07136779"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":["velavigo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07136779","phase":"1/2","setting":"PHASE 1/2A OPEN-LABEL CLINICAL TRIAL EVALUATING VBC101, AN EGFR AND CMET TARGETED BI-SPECIFIC ANTIBODY DRUG CONJUGATE, IN PARTICIPANTS WITH ADVANCED SOLID TUMOR MALIGNANCIES","sponsor":"VelaVigo Bio Inc","started":"2025-09-23","startedType":"actual","enrolled":310,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07136779/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"company":[{"id":"velavigo","kind":"company","name":"VelaVigo","route":"/companies/velavigo/"}]}}